Russian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Contemporary Clinical Trials 2013-Sep

Study protocol for multicentre randomized controlled trial of HeLP (Heat Loss Prevention) in the delivery room.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Ссылка сохраняется в буфер обмена
Sunita Vohra
Maureen Reilly
Valeria E Rac
Zafira Bhaloo
Denise Zayack
John Wimmer
Michael Vincer
Karla Ferrelli
Alex Kiss
Roger Soll

Ключевые слова

абстрактный

BACKGROUND

Immediate postnatal hypothermia is an independent risk factor for death in premature newborns. Three randomized controlled trials (RCTs) and five historical controlled trials show statistically significant differences in admission temperature between infants wrapped in occlusive skin wrap and unwrapped infants. This paper presents a study protocol for The Vermont Oxford Network (VON) Heat Loss Prevention (HeLP) Trial, a multicentre RCT of two interventions (standard of care vs. occlusive wrap) that investigates the effect of polyethylene occlusive wrap applied immediately after birth on mortality in infants born 24 + 0/7 to 27 + 6/7 week gestation.

METHODS

Inclusion criteria include: infants 24 + 0/7 to 27 + 6/7 weeks gestational age and a firm decision prior to birth to provide full resuscitative measures. Exclusion criteria comprise infants born with blistering skin conditions or congenital anomalies that are not covered by skin. The primary outcome measure is all-cause mortality until discharge from the hospital or at six months corrected gestational age. The secondary outcome measures include baseline and post-stabilization axillary temperatures, acidosis, hypotension, hypoglycaemia, seizures in the first 12h, patent ductus arteriosus, and respiratory distress syndrome. Long-term follow-up at 18 to 24 months corrected age will be assessed with the combined risk of death and major neurosensory disability as the primary outcome.

CONCLUSIONS

Key covariates and protocol deviations are addressed and steps to monitor these are described. Wrapping may prove an inexpensive and easy method to benefit premature newborns in level I and II nurseries, in both developed and developing countries, as well as large tertiary care centres.

UNASSIGNED

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada-355-2003 University of Alberta, Edmonton, Alberta, Canada-Pro00003810 Vermont Oxford Network, Burlington, Vermont, USA-CHRMS: M04-295.

Присоединяйтесь к нашей
странице facebook

Самая полная база данных о лекарственных травах, подтвержденная наукой

  • Работает на 55 языках
  • Травяные лекарства, подтвержденные наукой
  • Распознавание трав по изображению
  • Интерактивная карта GPS - отметьте травы на месте (скоро)
  • Прочтите научные публикации, связанные с вашим поиском
  • Ищите лекарственные травы по их действию
  • Организуйте свои интересы и будьте в курсе новостей исследований, клинических испытаний и патентов

Введите симптом или заболевание и прочтите о травах, которые могут помочь, введите лекарство и узнайте о болезнях и симптомах, против которых оно применяется.
* Вся информация основана на опубликованных научных исследованиях.

Google Play badgeApp Store badge